适应性伺服通气治疗中枢性睡眠呼吸暂停与睡眠质量变化:法国FACIL-VAA多中心队列6个月随访
这项法国前瞻性多中心观察性队列研究纳入526例有ASV适应证的以中枢性睡眠呼吸暂停(CSA)为主的患者,评估ASV治疗6个月后匹兹堡睡眠质量指数(PSQI)的变化。结果显示总体PSQI中位变化为-1分(IQR -3至0,P<.001),65%的参与者PSQI改善≥1分,除药物诱导性CSA外各适应证均有显著改善。
要点
- ASV治疗6个月后总体PSQI中位改善1分,65%患者改善≥1分。
- 药物诱导性CSA的PSQI变化未达统计学显著(P=.0866)。
- 不同ASV设备间睡眠质量改善趋势一致,适用于真实世界多种适应证。
核心结论
- 有ASV临床适应证的CSA患者在真实世界治疗中睡眠质量改善,且不依赖特定ASV设备。
研究设计与样本
- 法国前瞻性多中心观察性队列研究,2017年6月至2020年2月入组,纳入526例以CSA为主或CPAP未能控制中枢事件的OSA成人患者。
- 随访至基线及1、3、6、12个月,主要终点为基线至6个月PSQI评分变化,采用配对数据Wilcoxon符号秩检验。
主要发现
- 总体PSQI中位变化为-1(IQR -3至0;P<.001),65%的参与者PSQI改善≥1分。
- ASV适应证中心血管或神经系统病因CSA占38.4%,治疗相关CSA占36.1%,特发性CSA占14.1%,药物诱导性CSA占11.4%。
- 6个月随访时ASV使用中位数为6.1 h/晚。
- 药物诱导性CSA的PSQI中位变化为-1(IQR -2至1;P=.0866),未达统计学显著。
- 除药物诱导性CSA外,各ASV适应证的PSQI改善均有统计学意义。
关键数值与推荐
- 主要终点为基线至6个月PSQI评分变化,采用Wilcoxon符号秩检验。
- 总体PSQI中位变化-1(IQR -3至0;P<.001),65%参与者改善≥1分。
- 药物诱导性CSA的PSQI中位变化-1(IQR -2至1;P=.0866)。
- 6个月随访时ASV使用中位数为6.1 h/晚。
临床怎么用
- 对有ASV适应证的CSA患者,可预期6个月ASV治疗带来睡眠质量改善,药物诱导性CSA的获益尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A large number of symptomatic individuals with central sleep apnea (CSA) in clinical practice have an indication for adaptive servoventilation (ASV) therapy. RESEARCH QUESTION: What are the effects of ASV therapy on sleep quality and patient-reported outcome measures in patients with CSA across a range of devices and indications? STUDY DESIGN AND METHODS: This prospective multicenter observational cohort study was conducted in France and enrolled participants from June 2017 through February 2020. Adults with predominant CSA at diagnosis or OSA with central events not controlled with CPAP who had an indication for ASV were eligible. Participants attended clinic visits at baseline and after 1, 3, 6, and 12 months of follow-up. The primary end point was the change in Pittsburgh Sleep Quality Index (PSQI) score from baseline to 6-month follow-up (evaluated using a Wilcoxon signed-rank test on paired data). RESULTS: We included 526 individuals (median age, 69 years; 88.2% male). The indication for ASV included CSA with cardiovascular or neurologic cause (38.4%), treatment-emergent CSA (36.1%), idiopathic CSA (14.1%), or drug-induced CSA (11.4%). At the 6-month follow-up, study participants were using ASV for a median of 6.1 h/night. The median change in the PSQI score from baseline to 6 months in the overall study population was -1 (interquartile range, -3 to 0; P < .001), with significant results across all indications for ASV except for drug-induced CSA, where the median change was similar to the overall results, but did not achieve statistical significance (-1 [interquartile range, -2 to 1]; P = .0866). Overall, 65% of participants showed a ≥ 1-point improvement in the PSQI. INTERPRETATION: In this study, individuals with a clinical indication for ASV therapy experienced improved sleep quality during real-world treatment, regardless of which ASV device was used. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02835638; URL: www. CLINICALTRIALS: gov.
引用
- Tamisier R, Philippe C, Prigent A, et al. Change in Sleep Quality Associated With Adaptive Servoventilation for Central Sleep Apnea: Six-Month Follow-Up of the Multicenter Nationwide French "Etude de Cohorte Observationnelle Multicentrique Française de Patients Ayant un Syndrome d'Apnées du Sommeil Central ou Combiné Avec SAS Central Prédominant, Traités par Ventilation Auto-Asservie (FACIL-VAA)" Cohort. Chest. 2024. PMID: 39710250. doi:10.1016/j.chest.2024.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。